Currently, there are several ongoing clinical trials evaluating triple combination therapy consisting of endocrine therapy, CDK4/6i, and other inhibitors of the PI3K/AKT/mTOR pathway in ER+ advanced breast cancer following progression on a CDK4/6i regimen (NCT02871791, NCT02732119). This evidence concerns the gene PIK3CA and breast cancer.